Amphastar Pharmaceuticals, Inc. (AMPH) Q2 FY26 Earnings Call

New launches and portfolio diversification support growth, but IMS remediation, pricing pressure, and glucagon competition remain material offsets.

Q2 FY26 results, source: company transcript and SEC filings
QuarterQ2 FY26
Call date2026-08-06
Length30 minutes
EPS$0.80
EPS consensus$0.51
Revenue$183.9M

What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.

Other quarters: Q4 FY25

All AMPH earnings ยท Back to AMPH overview

Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.